Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission

H. J. Male, M. B. Davis, J. P. McGuirk, S. Abhyankar, O. S. Aljitawi, D. Zhang, Siddhartha Ganguly

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Blastic plasmacytoid dendritic cell (BPDC) neoplasm is a rare but clinically aggressive tumor known to be derived from the precursors of plasmacytoid dendritic cells (CD123+) with a high frequency of cutaneous and bone marrow involvement. Though majority of the patients initially respond to multi-agent chemotherapy, most would relapse within a year. We hereby report a patient with disseminated cutaneous BPDC with marrow involvement diagnosed by typical histo-pathological and flow-cytometric findings. He was subsequently treated with leukemia type induction regimen followed by allogeneic stem cell transplantation in first complete remission. He is now 18 months posttransplantation with continued remission with full donor chimerism. We recognize that BPDC with marrow involvement behaves like acute myeloid leukemia and aggressive treatment followed by stem cell transplantation may lead to long-term remission in selected cases.

Original languageEnglish (US)
Pages (from-to)398-400
Number of pages3
JournalInternational Journal of Hematology
Volume92
Issue number2
DOIs
StatePublished - Sep 2010

Keywords

  • Allogeneic stem cell transplantation
  • Blastic plasmacytoid dendritic cell neoplasm
  • Hematodermic neoplasm

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission'. Together they form a unique fingerprint.

Cite this